SKYE · Skye Bioscience, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These conditions give rise to substantial doubt as to the Company's ability to continue as a going concern within one year after the date that these financial statements are issued. After considering the plans to alleviate substantial doubt, management has concluded that there is substantial doubt about the Company's ability to continue as a going concern within one year after the date that these financial statements are issued.”View the 10-Q filed May 11, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-03-31 | DHILLON PUNIT |
Director, Chief Executive Officer |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option vests in equal monthly installments over the four year period beginning February 29, 2024. The grant date for the stock option is March 1, 2024. Upon a change in control of the Issuer, 100% of the stock options will become fully vested. |
Stock Option (Right to Buy)
|
125,000 |
| 2026-03-31 | Twitty Christopher |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option vests in equal monthly installments over the four year period beginning February 29, 2024. The grant date for the stock option is February 28, 2024. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. |
Stock Option (Right to Buy)
|
75,000 |
| 2026-03-31 | Diep Tuan Tu |
Chief Operating Officer |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option vests in equal monthly installments over the four year period beginning February 29, 2024. The grant date for the stock option is March 1, 2024. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. |
Stock Option (Right to Buy)
|
75,000 |
| 2026-03-31 | Twitty Christopher |
Director |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option vests 25% on December 8, 2023 and 1/48th monthly thereafter. The grant date for the stock option is January 5, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. |
Stock Option (Right to Buy)
|
12,000 |
| 2026-03-31 | Twitty Christopher |
Director |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is November 6, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. |
Stock Option (Right to Buy)
|
7,100 |
| 2026-03-31 | Diep Tuan Tu |
Chief Operating Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option is fully vested. |
Stock Option (Right to Buy)
|
7,080 |
| 2026-03-31 | Diep Tuan Tu |
Chief Operating Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option is fully vested. |
Stock Option (Right to Buy)
|
8,000 |
| 2026-03-31 | Twitty Christopher |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option is fully vested. Due to an administrative error, the Form 3 filed by the Reporting Person on April 25, 2025 inadvertently stated that the stock option vests in equal monthly installments over the one year period beginning February 21, 2025. In fact, the stock option vests in equal monthly installments over the four year period beginning February 24, 2025. |
Stock Option (Right to Buy)
|
150,000 |
| 2026-03-31 | Diep Tuan Tu |
Chief Operating Officer |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option vests in equal monthly installments over the four year period beginning February 21, 2025. The grant date for the stock option is February 25, 2025. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. |
Stock Option (Right to Buy)
|
150,000 |
| 2026-03-31 | DHILLON PUNIT |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option is fully vested. |
Stock Option (Right to Buy)
|
36,000 |
| 2026-03-31 | DHILLON PUNIT |
Director, Chief Executive Officer |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is November 6, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested |
Stock Option (Right to Buy)
|
9,013 |
| 2026-03-31 | DHILLON PUNIT |
Director, Chief Executive Officer |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option is fully vested. |
Stock Option (Right to Buy)
|
36,000 |
| 2026-03-31 | DHILLON PUNIT |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option is fully vested. |
Stock Option (Right to Buy)
|
250,000 |
| 2026-03-31 | Sharp John P |
Chief Financial Officer |
Other↑
|
No Securities Owned
|
0 |
| 2026-03-31 | Diep Tuan Tu |
Chief Operating Officer |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is August 25, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. |
Stock Option (Right to Buy)
|
22,021 |
| 2026-03-31 | Smith Karen L. |
EVP, Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests in equal monthly installments over the one year period beginning March 31, 2026. |
Stock Option (Right to Buy)
|
75,000 |
| 2026-03-31 | Schwab Andrew J. |
Director, 10% Owner |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests in equal monthly installments over the one year period beginning March 31, 2026. |
Stock Option (Right to Buy)
|
75,000 |
| 2026-03-31 | Diep Tuan Tu |
Chief Operating Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is August 25, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. |
Stock Option (Right to Buy)
|
22,021 |
| 2026-03-31 | Twitty Christopher |
Director |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option vests in equal monthly installments over the four year period beginning February 29, 2024. The grant date for the stock option is February 28, 2024. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. |
Stock Option (Right to Buy)
|
75,000 |
| 2026-03-31 | DHILLON PUNIT |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option vests in equal monthly installments over the four year period beginning February 29, 2024. The grant date for the stock option is March 1, 2024. Upon a change in control of the Issuer, 100% of the stock options will become fully vested. |
Stock Option (Right to Buy)
|
125,000 |
| 2026-03-31 | Twitty Christopher |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option vests in equal monthly installments over the four year period beginning October 28, 2024. The grant date for the stock option is October 28, 2024. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. |
Stock Option (Right to Buy)
|
200,000 |
| 2026-03-31 | Twitty Christopher |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option vests in equal monthly installments over the four year period beginning on August 24, 2023. The grant date for the stock option is August 25, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. |
Stock Option (Right to Buy)
|
17,004 |
| 2026-03-31 | Twitty Christopher |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option vests 25% on December 8, 2023 and 1/48th monthly thereafter. The grant date for the stock option is January 5, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. |
Stock Option (Right to Buy)
|
12,000 |
| 2026-03-31 | Jenkins Annalisa |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests in equal monthly installments over the one year period beginning March 31, 2026. |
Stock Option (Right to Buy)
|
75,000 |
| 2026-03-31 | Twitty Christopher |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is November 6, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. |
Stock Option (Right to Buy)
|
7,100 |
| 2026-03-31 | DHILLON PUNIT |
Director, Chief Executive Officer |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is August 25, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. |
Stock Option (Right to Buy)
|
21,586 |
| 2026-03-31 | Diep Tuan Tu |
Chief Operating Officer |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option vests in equal monthly installments over the four year period beginning October 28, 2024. The grant date for the stock option is October 29, 2024. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. |
Stock Option (Right to Buy)
|
125,000 |
| 2026-03-31 | Diep Tuan Tu |
Chief Operating Officer |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option is fully vested. |
Stock Option (Right to Buy)
|
8,000 |
| 2026-03-31 | DHILLON PUNIT |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option is fully vested. |
Stock Option (Right to Buy)
|
12,360 |
| 2026-03-31 | DHILLON PUNIT |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is August 25, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. |
Stock Option (Right to Buy)
|
21,586 |
| 2026-03-31 | DHILLON PUNIT |
Director, Chief Executive Officer |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option is fully vested. |
Stock Option (Right to Buy)
|
12,360 |
| 2026-03-31 | Twitty Christopher |
Director |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option vests in equal monthly installments over the four year period beginning on August 24, 2023. The grant date for the stock option is August 25, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. |
Stock Option (Right to Buy)
|
17,004 |
| 2026-03-31 | DHILLON PUNIT |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option vests in equal monthly installments over the four year period beginning October 28, 2024. The grant date for the stock option is October 27, 2024. Upon a change of control of the Issuer, 100% of the stock option will become fully vested. |
Stock Option (Right to Buy)
|
650,000 |
| 2026-03-31 | Grayson Paul A. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests in equal monthly installments over the one year period beginning March 31, 2026. |
Stock Option (Right to Buy)
|
75,000 |
| 2026-03-31 | Twitty Christopher |
Director |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option is fully vested. Due to an administrative error, the Form 3 filed by the Reporting Person on April 25, 2025 inadvertently stated that the stock option vests in equal monthly installments over the one year period beginning February 21, 2025. In fact, the stock option vests in equal monthly installments over the four year period beginning February 24, 2025. |
Stock Option (Right to Buy)
|
150,000 |
| 2026-03-31 | Diep Tuan Tu |
Chief Operating Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option vests in equal monthly installments over the four year period beginning February 21, 2025. The grant date for the stock option is February 25, 2025. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. |
Stock Option (Right to Buy)
|
150,000 |
| 2026-03-31 | Diep Tuan Tu |
Chief Operating Officer |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option is fully vested. |
Stock Option (Right to Buy)
|
7,080 |
| 2026-03-31 | Diep Tuan Tu |
Chief Operating Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option vests in equal monthly installments over the four year period beginning February 29, 2024. The grant date for the stock option is March 1, 2024. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. |
Stock Option (Right to Buy)
|
75,000 |
| 2026-03-31 | Diep Tuan Tu |
Chief Operating Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option vests in equal monthly installments over the four year period beginning October 28, 2024. The grant date for the stock option is October 29, 2024. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. |
Stock Option (Right to Buy)
|
125,000 |
| 2026-03-31 | Diep Tuan Tu |
Chief Operating Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option was omitted from the Reporting Person's original Form 3, filed on March 4, 2024. The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is November 6, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. |
Stock Option (Right to Buy)
|
9,194 |
| 2026-03-31 | Charych Deborah H. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests in equal monthly installments over the one year period beginning March 31, 2026. |
Stock Option (Right to Buy)
|
75,000 |
| 2026-03-31 | DHILLON PUNIT |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing. On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is November 6, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested |
Stock Option (Right to Buy)
|
9,013 |
| 2026-03-31 | DHILLON PUNIT |
Director, Chief Executive Officer |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option is fully vested. |
Stock Option (Right to Buy)
|
250,000 |
| 2026-03-31 | DHILLON PUNIT |
Director, Chief Executive Officer |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option vests in equal monthly installments over the four year period beginning October 28, 2024. The grant date for the stock option is October 27, 2024. Upon a change of control of the Issuer, 100% of the stock option will become fully vested. |
Stock Option (Right to Buy)
|
650,000 |
| 2026-03-31 | Twitty Christopher |
Director |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option vests in equal monthly installments over the four year period beginning October 28, 2024. The grant date for the stock option is October 28, 2024. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. |
Stock Option (Right to Buy)
|
200,000 |
| 2026-03-31 | Diep Tuan Tu |
Chief Operating Officer |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged. The stock option was omitted from the Reporting Person's original Form 3, filed on March 4, 2024. The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is November 6, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested. |
Stock Option (Right to Buy)
|
9,194 |
| 2026-02-06 | Diep Tuan Tu |
Chief Operating Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests in equal monthly installments over the four-year period beginning January 19, 2026. |
Stock Option (Right to Buy)
|
125,000 |
| 2026-02-06 | Twitty Christopher |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests in equal monthly installments over the four-year period beginning January 19, 2026. |
Stock Option (Right to Buy)
|
150,000 |
| 2026-02-06 | Charych Deborah H. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests in equal monthly installments over the one-year period beginning January 19, 2026. |
Stock Option (Right to Buy)
|
35,000 |
| 2026-02-06 | DHILLON PUNIT |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The stock option vests in equal monthly installments over the four-year period beginning January 19, 2026. |
Stock Option (Right to Buy)
|
280,000 |